# US 2021/0260113 A1 · Devices, methods, compositions and systems for the treatment of aging and age-related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260113 A1
- Document ID: US20210260113A1
- Status: Published application
- Kind: A1
- Application number: 17/150,466
- Filed: 2021-01-15
- Published: 2021-08-26
- Earliest claimed: 2018-07-17
- Assignees: Gero LLC
- Applicants: Gero LLC
- Inventors: Maksim Nikolaevich KHOLIN; Petr Olegovich FEDICHEV; Olga Andreevna BURMISTROVA; Konstantin Alexandrovich AVKHACHEV; Dmitry Veniaminovich SHISHOV; Andrey Evgenievich TARKHOV
- Web page: https://patentgrep.com/patent/US20210260113A1

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- A61P 39/00: General protective or antinoxious agents
- C07K 16/18: against material from animals or humans
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/38: against protease inhibitors of peptide structure
- G01N 33/543: with an insoluble carrier for immobilising immunochemicals
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 2333/51: Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/71: for growth factors; for growth regulators
- G01N 2333/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- G01N 2333/96494: Matrix metalloproteases, e. g. 3.4.24.7
- G01N 2800/7042: Aging, e.g. cellular aging
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides methods, devices, kits, and agents for the treatment of aging and aging related diseases and disorders and related systems and methods.

## Claims

### Claim 1

A protein binding device, wherein the protein binding device comprises a housing, wherein the housing defines a lumen and the housing further comprises an inlet port for receiving fluid to the lumen, and an outlet port for releasing fluid from the lumen, wherein the lumen comprises binding elements, wherein the binding elements selectively bind a protein selected from the group consisting of: CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB.

### Claim 2

A pharmaceutical composition provided as part of an anti-aging treatment or for treating or preventing an age-related disease or disorder comprising an agent configured to bind to, inhibit, or degrade a protein selected from the group consisting of: B2M, CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB; and at least one pharmaceutically acceptable excipient.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the protein is FSTL3, wherein the pharmaceutical composition is devoid of or excludes compounds or molecules for treating insulin resistance, diastolic heart failure, and obesity.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein the agent is selected from the group consisting of: a protein, a polymer, an aptamer, a SOMAmer, a peptide, a virus, a small molecule, a nanoparticle, an antibody, a monoclonal antibody, a polyclonal antibody, a humanized monoclonal antibody, a human monoclonal antibody, a human or humanized polyclonal antibody, an anti-GDF15 human antibody, an anti-FSTL3 human antibody, an anti-BMP4 human antibody, and an anti-FRZB (sFRP3) human antibody.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the agent is bound to a particle.

### Claim 6

A pharmaceutical composition comprising a blood plasma fraction, wherein the blood plasma fraction comprises a negligible amount of a protein selected from the group consisting of CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the negligible amount is between about 0.008 pg/mL and about 15,000 ng/mL.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, comprising one or more biomarkers characteristic of aged blood.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein one of the biomarkers characteristic of aged blood is a biological age of the subject from whose blood the pharmaceutical composition is produced, wherein the biological age of the subject is greater than 45 years of age.

### Claim 10

A method of providing an anti-aging treatment or of treating or preventing an age-related disease or disorder of a subject comprising reducing, inhibiting, or degrading a protein selected from the group consisting of: CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB in the blood of the subject.

### Claim 11 (depends on 10)

The method of claim 10, further comprising administering to the subject a gene therapy.

### Claim 12 (depends on 10)

The method of claim 10, wherein the age-related disease or disorder is associated with an alleviated level of a protein selected from the group consisting of: CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB in a bodily fluid of the subject.

### Claim 13 (depends on 10)

The method of claim 10, wherein the age-related disease or disorder is selected from the group consisting of frailty, Alzheimer's disease, Parkinson's disease, Huntington's diseases, cardiovascular disease, renal failure, muscle wasting or cachexia, osteopenia or osteoporosis, obesity, insulin resistance or diabetes, diverse adult-onset cancers, atherosclerosis, cardiovascular disease, adult cancer, arthritis, cataracts, osteoporosis, type 2 diabetes, hypertension, age-progressive dementia; amyotrophic lateral sclerosis, stroke, atrophic gastritis, osteoarthritis, NASH, camptocormia, chronic obstructive pulmonary disease, coronary artery disease, dopamine dysregulation syndrome, metabolic syndrome, effort incontinence, Hashimoto's thyroiditis, heart failure, late life depression, immunosenescence, age related decline in immune response to vaccines, age related decline in response to immunotherapy, myocardial infarction, acute coronary syndrome, sarcopenia, sarcopenic obesity, senile osteoporosis, urinary incontinence, stroke, atrophic gastritis, camptocormia, chronic obstructive pulmonary disease, coronary artery disease, dopamine dysregulation syndrome, late life depression, osteoarthritis, chronic fatigue syndrome, senile dementia, mild cognitive impairment due to aging, Creutzfeldt-Jakob disease, stroke, CNS cerebral senility, pre-diabetes, diabetes, peripheral arterial disease, aortic valve disease, stroke, Lewy body disease, progressive subcortical gliosis, progressive supranuclear palsy, thalamic degeneration syndrome, hereditary aphasia, myoclonus epilepsy, macular degeneration, pressure ulcers, delirium, progressive subcortical gliosis, progressive supranuclear palsy, thalamic degeneration syndrome, hereditary aphasia, myoclonus epilepsy, and metabolic disorder.

### Claim 14 (depends on 10)

The method of claim 10, wherein the anti-aging treatment is selected from the group consisting of a treatment leading to prevention, amelioration or lessening the effects of aging; decreasing or delaying an increase in a biological age of the subject; slowing a rate of aging of the subject; prevention, amelioration or lessening the effects of frailty; prevention, amelioration or lessening the effects of at least one of an aging-related disease or conditions; increasing a health span or lifespan of the subject; increasing a stress resistance or resilience of the subject; increasing a rate or other enhancement of recovery after surgery, radiotherapy, disease and/or any other stress; prevention, amelioration or lesion the effects of menopausal syndrome; restoring reproductive function; elimination or lessening the spread of senescent cells; modulation of at least one biomarker of aging; a decrease in a rate of wrinkle development; and decrease in a rate of hair greying.

### Claim 15 (depends on 10)

The method of claim 10, wherein the anti-aging treatment is selected from the group consisting of a treatment related to changing a blood parameter, a heart rate, a cognitive function, a bone density, a basal metabolic rate, a systolic blood pressure, a heel bone mineral density (BMD), a heel quantitative ultrasound index (QUI), a heel broadband ultrasound attenuation, a forced expiratory volume in 1-second (FEV1), forced vital capacity (FVC), a peak expiratory flow (PEF), a duration to first press of snap-button in each round, a reaction time, a mean time to correctly identify matches, a right or left hand grip strength, a whole body fat-free mass, a leg fat-free mass, a time for recovery after a stress-inducing event, a resistance to radiation, a morbidity risk, and a mortality risk of the subject.

### Claim 16

A method of providing an anti-aging treatment or of treating or preventing an age-related disease or disorder of a subject, comprising administering to the subject a pharmaceutical composition comprising an inhibitor of a protein selected from the group consisting of: B2M, CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB; and at least one pharmaceutically acceptable excipient.

### Claim 17

A method of providing an anti-aging treatment or of treating or preventing an age-related disease or disorder of a subject, comprising administering to the subject a pharmaceutical composition comprising a blood plasma fraction, wherein the blood plasma fraction comprises a negligible amount of a protein selected from the group consisting of: CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB, wherein the negligible amount is between about 0.008 pg/mL and about 15,000 ng/mL.

### Claim 18

A kit, comprising:
a pharmaceutical composition comprising:
an agent configured to bind to, inhibit, or degrade a protein selected from the group consisting of: B2M, CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB, wherein the agent is selected from the group consisting of: a protein, a polymer, an aptamer, a SOMAmer, a peptide, a virus, a small molecule, a nanoparticle, an antibody, a monoclonal antibody, a polyclonal antibody, a humanized monoclonal antibody, a human monoclonal antibody, a human or humanized polyclonal antibody, an anti-GDF15 human antibody, an anti-FSTL3 human antibody, an anti-BMP4 human antibody, and an anti-FRZB (sFRP3) human antibody, and
at least one pharmaceutically acceptable excipient; and
an instruction for using the pharmaceutical composition as part of the anti-aging treatment or to treat or prevent an age-related disease or disorder.

### Claim 19

A tangible medium comprising a computer program, which, when executed by one or more processors of a computing device, causes the computing device to attribute information regarding a protein binding device, another device, or a therapeutic agent with information about reducing, binding, inhibiting, or degrading at least one protein within the blood of the subject, wherein the protein is selected from the group consisting of: CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB, and wherein the information about reducing, binding, inhibiting or degrading the protein is associated with an anti-aging treatment.

### Claim 20 (depends on 19)

The tangible medium of claim 19, wherein the tangible medium is a computer storage medium.
